文献速递免疫规划卫生政策与健康促进

PCV21对比PCV20对西班牙≥45岁成人侵袭性肺炎球菌疾病的终身健康与经济影响

Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged ≥45 years in Spain.
PubMed 文献 · Vaccine · 2026-08-30

本研究用已发表的Markov模型评估西班牙45-64岁和≥65岁成人接种PCV21或PCV20后终身IPD病例、死亡及直接医疗成本。结果显示两个年龄组中PCV21较PCV20预防更多IPD病例和死亡,并节省更多直接医疗成本,提示将PCV21纳入西班牙成人肺炎球菌疫苗接种策略可能带来更大健康与经济收益。

要点

  • 45-64岁组PCV21较PCV20多预防13%的IPD病例和17%的IPD相关死亡。
  • ≥65岁组PCV21较PCV20多预防24%的IPD病例和25%的IPD相关死亡。
  • PCV21在两组中均较PCV20节省更多直接医疗成本(分别多10%和25%)。

核心结论

  • 在45-64岁和≥65岁成人中,PCV21较PCV20对IPD显示出更大的健康与经济影响,支持将PCV21纳入西班牙成人肺炎球菌疫苗接种策略。

研究设计与样本

  • 采用已发表的Markov模型,估算西班牙45-64岁和≥65岁成人接种PCV21或PCV20后的终身IPD病例、IPD相关死亡及直接医疗成本(2024年欧元)。

主要发现

  • 45-64岁组:PCV21预计预防1590例IPD和134例IPD相关死亡,PCV20为1412例和114例;PCV21较PCV20多减少13%的IPD病例和17%的IPD相关死亡。
  • ≥65岁组:PCV21预计预防10262例IPD和2207例IPD相关死亡,PCV20为8243例和1772例;PCV21较PCV20多减少24%的IPD病例和25%的IPD相关死亡。
  • ≥65岁组:PCV21节省直接医疗成本1301百万欧元,PCV20为1044百万欧元,成本减少幅度高25%。

临床怎么用

  • 在西班牙成人肺炎球菌疫苗接种决策中,可参考本模型结果评估PCV21相较PCV20在≥45岁人群中额外减少IPD负担和节省直接医疗成本的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: PCV21, a 21-valent pneumococcal conjugate vaccine (PCV), includes eight unique serotypes not covered by other currently licensed pneumococcal vaccines, and accounts for approximately 79% of IPD cases among adults aged ≥65 years in Spain, compared with 65% for PCV20. This study evaluated the potential lifetime health and economic impact of PCV21 compared with PCV20 vaccination on IPD among adults aged ≥45 years in Spain. METHODS: A published Markov model estimated the lifetime IPD cases, IPD-related deaths, and associated direct medical costs (2024 Euros) for Spanish adults aged 45-64 and ≥ 65 years vaccinated with either PCV21 or PCV20. A sensitivity analysis assessed the effect of varying inputs on the direct costs averted by PCV21 compared with PCV20. RESULTS: For adults aged 45-64 years, PCV21 was projected to prevent 1590 IPD cases and 134 IPD-related deaths, compared with 1412 cases and 114 deaths prevented with PCV20. Compared with PCV20, PCV21 averted 13% more IPD cases and 17% more IPD-related deaths. The greater reduction in IPD burden translated into €7.3 million in direct medical costs saved with PCV21, 10% higher than the €6.6 million saved with PCV20. Among adults aged ≥65 years, PCV21 was projected to prevent 10,262 IPD cases and 2207 IPD-related deaths, compared with 8243 cases and 1772 deaths prevented with PCV20. Compared with PCV20, PCV21 averted 24% more IPD cases and 25% more IPD-related deaths. The corresponding economic impact was also higher with PCV21, with €1301 million in direct medical costs saved compared with €1044 million for PCV20, representing a 25% greater reduction in costs. CONCLUSIONS: In both age groups, PCV21 showed greater health and economic impact associated with IPD compared with PCV20, underscoring the potential benefits of incorporating PCV21 into adult pneumococcal vaccination strategies in Spain.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Simuzingili M, Fernández-Soberón S, Yi Z, et al. Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged ≥45 years in Spain. Vaccine. 2026. PMID: 42669238. doi:10.1016/j.vaccine.2026.129077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。